Ali Erginay · enciclopedia

Publicaciones › Retinopatía diabética: clínica, función y progresión

Widefield OCT-Angiography and Fluorescein Angiography Assessments of Nonperfusion in Diabetic Retinopathy and Edema Treated with Anti–Vascular Endothelial Growth Factor

Angiografía de campo amplio OCT y angiografía con fluoresceína para evaluar la no perfusión en retinopatía diabética y edema tratados con anti-factor de crecimiento endotelial vascular

Año2019
FuenteOphthalmology
Tipoarticle · Journal Article, Research Support, Non-U.S. Gov't
Autores (8)Aude Couturier, Pierre-Antoine Rey, Ali Erginay, Carlo Lavia, Sophie Bonnin, Bénédicte Dupas, Alain Gaudric, Ramin Tadayoni
Posición de Erginay3 de 8
Citas220 (OpenAlex)
EnlacesDOI 10.1016/j.ophtha.2019.06.022 · PubMed 31383483 · OpenAlex · Texto completo en acceso abierto
LíneasEdema macular diabético y sus tratamientos Enfermedades vasculares, genéticas e inflamatorias de la retina Retinopatía diabética: clínica, función y progresión Imagen retiniana: OCT, OCT-angiografía y ultra-gran campo

En pocas palabras

Se estudió el cambio en la no perfusión retiniana después del tratamiento con anti-factor de crecimiento endotelial vascular para el edema macular diabético. Se utilizaron dos técnicas de imagen: angiografía OCT de campo amplio y angiografía con fluoresceína de campo ultra amplio. Se encontró que no hubo reperfusión de los vasos sanguíneos en las áreas de no perfusión después del tratamiento.

Resumen divulgativo generado automáticamente a partir del resumen original; puede contener imprecisiones.

Resumen original

To assess change in retinal nonperfusion (NP) after anti-vascular endothelial growth factor (VEGF) therapy for diabetic macular edema (DME) using 2 different imaging modalities: swept-source widefield (SS-WF) OCT angiography (OCTA) and ultra-widefield (UWF) fluorescein angiography (FA). Observational case series. Ten eyes of 9 patients with severe nonproliferative diabetic retinopathy (NPDR) or proliferative DR (PDR) initiating 3 monthly anti-VEGF intravitreal injections for DME. All eyes were imaged with UWF color fundus photographs (CFPs), UWF FA, and SS-WF OCTA at baseline (M0) and 1 month after the third anti-VEGF injection (M3). All images were aligned and divided into 16 boxes for analysis of NP areas by 2 blinded retina specialists. The number of discrepancies between SS-WF OCTA and UWF FA regarding the detection of NP areas and small vessels passing through NP areas; assessment of DR severity on UWF CFP; and change in each NP area between M0 and M3: number of boxes/eye with presence of at least 1 NP area, number of arterioles or venules that disappeared or reappeared, and number of NP areas in which capillaries disappeared or reappeared. The diabetic retinopathy (DR) severity score improved by at least 1 stage in 8 of 10 eyes, with a significant decrease in the mean number of microaneurysms and retinal hemorrhages on UWF CFP at M3 versus M0 (n = 40±28 vs. 121±57; P = 0.0020) and regression of fundus neovascularization when present. All NP areas detected on FA were seen on SS-WF OCTA, but additional NP areas were detected on SS-WF OCTA at M0 in 29% (46/160) of boxes. No reperfusion of arterioles or venules was observed at M3 on FA or SS-WF OCTA. Retinal capillaries were only visible on OCTA, and no reperfusion in NP areas was observed even when a reduction in dark areas was visible on FA. No reperfusion of vessels or capillary network was detected in NP areas using 2 imaging techniques, UWF FA and SS-WF OCTA, in eyes with DR after 3 anti-VEGF injections. The detection rate of NP areas was higher with SS-WF OCTA than with UWF FA.

Términos MeSH

Aged Angiogenesis Inhibitors Diabetic Retinopathy Female Fluorescein Angiography Humans Intravitreal Injections Macular Edema Male Middle Aged Perfusion Index Ranibizumab Receptors, Vascular Endothelial Growth Factor Recombinant Fusion Proteins Retinal Vessels Tomography, Optical Coherence Vascular Endothelial Growth Factor A Visual Acuity